Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone. Can This Modality Improve the Antiemetic Effect

NCT05872893 is registered in ClinicalTrials.gov with Immune Oncology Research Institute as lead sponsor.

NCT NCT05872893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05872893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone. Can This Modality Improve the Antiemetic Effect
Lead sponsor
Immune Oncology Research Institute
Phase
Phase 3
Overall status
Completed
Start date
June 27, 2023
Completion date
January 30, 2025
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric cancer